Loxo@Lilly Unveils Three New Oncology Programs At 2023 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics
Portfolio Pulse from Benzinga Newsdesk
Loxo@Lilly is set to present three new oncology programs at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The presentations will include data for a potent inhibitor of KRAS G12D, a pan-KRAS inhibitor, and a fully human monoclonal anti-Nectin-4 antibody conjugated to a topoisomerase I inhibitor.
October 04, 2023 | 4:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The unveiling of three new oncology programs by Loxo@Lilly could potentially boost the company's position in the oncology market. The programs include a potent KRAS G12D inhibitor, a pan-KRAS inhibitor, and an anti-Nectin-4 antibody.
The unveiling of new oncology programs indicates that Loxo@Lilly is actively investing in research and development, which could potentially lead to new product offerings in the future. This could strengthen the company's position in the oncology market and potentially boost its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100